Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alisporivir - Debiopharm

Drug Profile

Alisporivir - Debiopharm

Alternative Names: DEB-025; DEBIO-025; DEBIO-25

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Debiopharm
  • Developer Debiopharm; Solid Biosciences
  • Class Ciclosporins
  • Mechanism of Action Cyclophilin inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Gastrointestinal disorders
  • Discontinued Duchenne muscular dystrophy; Hepatitis C; HIV infections

Most Recent Events

  • 29 Nov 2022 Alisporivir is still in phase II trials for Covid-19 infections (In the elderly, In adults) in France (EudraCT2020-002295-13)
  • 13 Apr 2022 Debiopharm completes a phase II trial for Covid-19 infections (In the elderly, In adults) in France (NCT04608214) (EudraCT2020-002295-13)
  • 08 Jan 2021 Phase-II clinical trials in COVID-2019 infections (In adults, In the elderly) in France (PO) (EudraCT2020-002295-13)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top